{"id":"cy-atg","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Serum sickness"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL5855218","moleculeType":null,"molecularWeight":"426.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cy-ATG combines cyclophosphamide (cytoxan) with anti-thymocyte globulin (ATG), a polyclonal antibody preparation that targets T cells. This combination is used in immunosuppressive conditioning regimens to deplete pathogenic T cells in aplastic anemia and other bone marrow failure syndromes, allowing hematopoietic recovery or facilitating stem cell engraftment.","oneSentence":"Cy-ATG is a cytoxan-based anti-thymocyte globulin that depletes T lymphocytes to suppress immune-mediated destruction of bone marrow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:10.802Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Aplastic anemia"},{"name":"Bone marrow failure syndromes"}]},"trialDetails":[{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT02828592","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Northside Hospital, Inc.","startDate":"2016-09-09","conditions":"Severe Aplastic Anemia","enrollment":20},{"nctId":"NCT06984536","phase":"PHASE2","title":"Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-21","conditions":"Myelodysplastic Syndrome, Acute Leukemia","enrollment":40},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT06108739","phase":"PHASE3","title":"ATG Plus Low-dose PT-Cy for GVHD Prevention","status":"TERMINATED","sponsor":"Peking University People's Hospital","startDate":"2023-11-01","conditions":"Hematologic Malignancy","enrollment":66},{"nctId":"NCT06946602","phase":"NA","title":"Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-20","conditions":"AML, Elderly","enrollment":307},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT03367546","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-07-02","conditions":"Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders","enrollment":5},{"nctId":"NCT06238245","phase":"PHASE2","title":"Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-02-28","conditions":"Graft-versus-host Disease, Hematological Malignancies","enrollment":22},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT05029206","phase":"","title":"Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-05-05","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":174},{"nctId":"NCT06069180","phase":"PHASE4","title":"The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-11-15","conditions":"Severe Aplastic Anemia","enrollment":160},{"nctId":"NCT03608059","phase":"PHASE4","title":"ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-07-28","conditions":"Myeloid Tumor","enrollment":418},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT05063513","phase":"PHASE2, PHASE3","title":"Autologous Stem Cell Transplantation: International Lupus Trial","status":"WITHDRAWN","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2009-07","conditions":"REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS","enrollment":""},{"nctId":"NCT05629260","phase":"","title":"The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-12-01","conditions":"Hematological Malignancy","enrollment":300},{"nctId":"NCT05921318","phase":"","title":"Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-06-01","conditions":"Hematologic Malignancy, Stem Cell Transplant Complications","enrollment":20},{"nctId":"NCT00114530","phase":"PHASE2, PHASE3","title":"Scleroderma: Cyclophosphamide or Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-06","conditions":"Scleroderma, Systemic, Sclerosis, Autoimmune Disease","enrollment":75},{"nctId":"NCT02833805","phase":"PHASE2","title":"NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09","conditions":"Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure","enrollment":21},{"nctId":"NCT04118075","phase":"PHASE2","title":"PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2019-01-01","conditions":"GVHD, Acute","enrollment":23},{"nctId":"NCT00176930","phase":"NA","title":"Stem Cell Transplant for Hematological Malignancy","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2001-10","conditions":"Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute","enrollment":330},{"nctId":"NCT02181478","phase":"EARLY_PHASE1","title":"Intra-Osseous Co-Transplant of UCB and hMSC","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-07-22","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":6},{"nctId":"NCT03793517","phase":"PHASE2, PHASE3","title":"Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2018-09-01","conditions":"Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse","enrollment":55},{"nctId":"NCT00176852","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant for Hemoglobinopathy","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-06","conditions":"Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia","enrollment":22},{"nctId":"NCT02080195","phase":"PHASE1, PHASE2","title":"Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09-13","conditions":"Lupus Erythematosus, Graft-versus-host Disease","enrollment":1},{"nctId":"NCT03799224","phase":"PHASE2, PHASE3","title":"Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-12-01","conditions":"Stem Cell Transplant Complications, Relapse Leukemia, Refractory Leukemia","enrollment":55},{"nctId":"NCT00489281","phase":"PHASE2","title":"Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-06-23","conditions":"Sickle Cell Disease","enrollment":43},{"nctId":"NCT03818334","phase":"PHASE2, PHASE3","title":"Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2018-11-06","conditions":"Bone Marrow Transplant Complications, Graft Versus Host Disease, Infection Viral","enrollment":50},{"nctId":"NCT02029638","phase":"PHASE2","title":"BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-07","conditions":"Kidney Transplantation","enrollment":4},{"nctId":"NCT01037764","phase":"PHASE2","title":"Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2010-01","conditions":"Acute Lymphoid Leukemia","enrollment":100},{"nctId":"NCT01883180","phase":"PHASE4","title":"ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-06","conditions":"Hematopoietic Stem Cell Transplantation, Antithymocyte Globulin, Viral Infection","enrollment":412},{"nctId":"NCT03190733","phase":"PHASE4","title":"A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2017-08-30","conditions":"Chronic Graft-versus-host-disease, Leukemia Relapse","enrollment":192},{"nctId":"NCT03171831","phase":"PHASE4","title":"Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2017-04-01","conditions":"Thalassemia Major","enrollment":30},{"nctId":"NCT02676622","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Refractory Crohn's Disease","status":"WITHDRAWN","sponsor":"Nationwide Children's Hospital","startDate":"2013-04","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02838992","phase":"PHASE4","title":"ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia","status":"UNKNOWN","sponsor":"Jinan Military General Hospital","startDate":"2017-02","conditions":"Aplastic Anemia","enrollment":130},{"nctId":"NCT01341899","phase":"PHASE2","title":"Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2006-06","conditions":"Type 1 Diabetes","enrollment":50},{"nctId":"NCT02643589","phase":"NA","title":"Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-06","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT00028730","phase":"PHASE2","title":"Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-08","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":25},{"nctId":"NCT01145976","phase":"PHASE3","title":"Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia","status":"UNKNOWN","sponsor":"Cooperative Study Group A for Hematology","startDate":"2010-03","conditions":"Aplastic Anemia","enrollment":98},{"nctId":"NCT00774527","phase":"PHASE3","title":"Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT","status":"COMPLETED","sponsor":"Cooperative Study Group A for Hematology","startDate":"2003-03","conditions":"Bone Marrow Failure Syndromes","enrollment":82},{"nctId":"NCT00275678","phase":"PHASE3","title":"Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2003-11","conditions":"Blood Stem Cell Transplant","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cyclophosphamide","Thymoglobulin"],"phase":"phase_3","status":"active","brandName":"Cy-ATG","genericName":"Cy-ATG","companyName":"Cooperative Study Group A for Hematology","companyId":"cooperative-study-group-a-for-hematology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cy-ATG is a cytoxan-based anti-thymocyte globulin that depletes T lymphocytes to suppress immune-mediated destruction of bone marrow. Used for Aplastic anemia, Bone marrow failure syndromes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}